Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study

被引:15
|
作者
Franssens, Bas T. [1 ]
van der Graaf, Yolanda [2 ]
Kappelle, L. Jaap [3 ]
Westerink, Jan [1 ]
de Borst, Gert J. [4 ]
Cramer, Maarten J. [5 ]
Visseren, Frank L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands
关键词
ALL-CAUSE MORTALITY; C-REACTIVE PROTEIN; ADIPOSE-TISSUE; VASCULAR-DISEASE; HEALTHY OBESITY; INSULIN-RESISTANCE; ARTERIAL-DISEASE; METAANALYSIS; INFLAMMATION; INDIVIDUALS;
D O I
10.2337/dc15-0684
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVETo quantify the role of BMI and metabolic dysfunction in the risk of development of type 2 diabetes in patients at high risk or with manifest vascular disease.RESEARCH DESIGN AND METHODSA total of 6,997 patients participating in the prospective Secondary Manifestations of ARTerial disease (SMART) cohort study were classified according to BMI and metabolic dysfunction, defined as three or more of the modified National Cholesterol Education Program (NCEP) metabolic syndrome criteria (waist circumference replaced by hs-CRP 2 mg/L). Risk of type 2 diabetes (assessed with biannually questionnaires) was estimated with Cox proportional hazards analysis.RESULTSDuring a median follow-up of 6.0 years (interquartile range 3.1-9.1 years), 519 patients developed type 2 diabetes (incidence rate 12/1,000 person-years). In the absence of metabolic dysfunction (2 NCEP criteria), adiposity increased the risk of type 2 diabetes compared with normal-weight patients (HR 2.5 [95% CI 1.5-4.2] for overweight and HR 4.3 [95% CI 2.2-8.6] for obese patients). In the presence of metabolic dysfunction (3 NCEP criteria), an increased risk of type 2 diabetes was observed in patients with normal weight (HR 4.7 [95% CI 2.8-7.8]), overweight (HR 8.5 [95% CI 5.5-13.4]), and obesity (HR 16.3 [95% CI 10.4-25.6]) compared with normal-weight patients without metabolic dysfunction.CONCLUSIONSAdiposity, even in the absence of metabolic dysfunction, is a risk factor for type 2 diabetes. Moreover, presence of metabolic dysfunction increases the risk of type 2 diabetes in all BMI categories. This supports the assessment of adiposity and metabolic dysfunction in patients with vascular disease or at high risk for cardiovascular events.
引用
收藏
页码:1945 / 1951
页数:7
相关论文
共 50 条
  • [1] Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Sanchez, Robert J.
    Khan, Irfan
    Karter, Andrew J.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2020, 133 (02): : 200 - 206
  • [2] Body Weight Variability and the Risk of Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes: A Nationwide Cohort Study
    Nam, Ga Eun
    Kim, Wonsock
    Han, Kyungdo
    Lee, Chung-woo
    Kwon, Yeongkeun
    Han, Byoungduck
    Park, Seokwon
    Park, Joo-Hyun
    Kim, Yang-Hyun
    Kim, Do-Hoon
    Kim, Seon Mee
    Choi, Youn Seon
    Cho, Kyung Hwan
    Park, Yong Gyu
    [J]. DIABETES CARE, 2020, 43 (09) : 2234 - 2241
  • [3] Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study
    Fangel, Mia Vicki
    Nielsen, Peter Bronnum
    Kristensen, Jette Kolding
    Larsen, Torben Bjerregaard
    Overvad, Thure Filskov
    Lip, Gregory Y. H.
    Jensen, Martin Bach
    [J]. AMERICAN JOURNAL OF MEDICINE, 2020, 133 (06): : E269 - E279
  • [4] Cardiovascular disease risk communication for patients with type 2 diabetes: The @RISK Study
    Welschen, L. M. C.
    Bot, S. D. M.
    van der Weijden, T.
    Timmermans, D. R. M.
    Dekker, J. M.
    Nijpels, G.
    [J]. DIABETOLOGIA, 2010, 53
  • [5] Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease
    Meigs, James B.
    Wilson, Peter W. F.
    Fox, Caroline S.
    Vasan, Ramachandran S.
    Nathan, David M.
    Sullivan, Lisa M.
    D'Agostino, Ralph B.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (08): : 2906 - 2912
  • [6] Assessment of cardiovascular events in a real-world high-risk cohort with type 2 diabetes or atheroscleortic cardiovascular disease in Germany
    Verket, M.
    Kossack, N.
    Brandts, J.
    Schoenfelder, T.
    Schuett, K.
    Haeckl, D.
    Marx, N.
    Mueller-Wieland, D.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S449 - S449
  • [7] Pulse pressure predicts the risk of cardiovascular events in a large cohort of patients with type 2 diabetes
    Cockcroft, JR
    Evans, M
    McEwan, P
    Currie, CJ
    Davies, S
    Rees, AE
    Wilkinson, IB
    Scanlon, MF
    Peters, JR
    [J]. DIABETES, 2001, 50 : A150 - A150
  • [8] Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Zinman, Bernard
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    Fitchett, David
    Kohler, Sven
    Mattheus, Michaela
    Biomath, Dipl
    Woerle, Hans J.
    Broedl, Uli C.
    Johansen, Odd Erik
    Albers, Gregory W.
    Diener, Hans Christoph
    [J]. STROKE, 2017, 48 (05) : 1218 - +
  • [9] Pulse pressure predicts the risk of cardiovascular events in a large cohort of patients with type 2 diabetes
    Cockcroft, JR
    McEwan, P
    Evans, LM
    Hopkinson, P
    Peters, JR
    Currie, CJ
    [J]. DIABETOLOGIA, 2001, 44 : A46 - A46
  • [10] No Increased Risk of Cardiovascular Events with Dapagliflozin in Elderly Patients with Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Johansson, Peter A.
    Sugg, Jennifer E.
    Johnsson, Eva
    [J]. DIABETES, 2015, 64 : A4 - A4